Six-month clinical outcomes after ST-elevation myocardial infarction in eastern Indonesia: a prospective cohort study Authors: Abdul Hakim Alkatiri, Andriany Qanitha, Akhtar Fajar Muzakkir, Andi Tihardimanto Kaharuddin, Az Hafid Nashar, Nurul Qalby, Nabilah Puteri Larassaphira, Muzakkir Amir, Idar Mappangara Published: 2025 ABSTRACT This study aimed to evaluate the six-month major adverse cardiovascular and cerebrovascular events (MACCE) among ST-elevation myocardial infarction (STEMI) patients, and identify their predictors. This single-centre, prospective observational study involved STEMI patients who presented to the Makassar Cardiac Centre in Indonesia from July 2018 to June 2020. Consecutive sampling was employed. The primary endpoint was MACCE (including all-cause mortality, heart failure requiring hospitalization, reinfarction, and stroke) during hospitalization, at 30-day and 6-month follow-up. We recruited 365 patients with a mean age of 57.1 ± 10.3 years, and predominantly male (n = 294, 80.5%). Majority of the patients (n = 206, 56.4%) received reperfusion therapy, with 104 (28.5%) underwent primary percutaneous coronary intervention (PPCI) and 102 (27.9%) received fibrinolysis. Six-month mortality was higher without reperfusion than with PPCI or fibrinolysis (26.4% vs 17.3% vs 13.7%, p = 0.030). MACCE occurred in 23.6% at 30 days and 57.0% at 6 months. Most STEMI patients in East Indonesia were latecomers, with a median time from onset to hospitalization of 350 min. Independent predictors of 6-month MACCE were age ≥ 60 years (HR 1.45, p = 0.032), Killip class ≥ 2 (HR 2.06, p < 0.001), anterior MI (HR 1.47, p = 0.024), renal impairment (HR 1.57, p = 0.015), medication non-adherence (HR 1.70, p = 0.001), and hospital stay ≥ 8 days (HR 1.48, p = 0.018). The high incidence of MACCE at 6 months following STEMI in our region is worrisome. Identified MACCE predictors can guide better STEMI management. To reduce MACCE following STEMI, it is crucial to raise symptom awareness, expedite PPCI activation, and strengthen hospital infrastructure and resources for STEMI care. Introduction Acute coronary syndrome (ACS) contributes to approximately 7 million deaths annually. ACS has emerged as a leading cause of mortality in the Asia–Pacific region, accounting for nearly half of the global burden1. Data from registries in the Asia–Pacific region indicate that ACS-related mortality rates have remained consistently high at 5% during hospitalization, doubling to 10% at 1 year post-discharge. Registry-based data also reveal significant regional variations in the utilization of invasive and pharmacologic treatment approaches, as well as in short- and long-term clinical outcomes across the Asia–Pacific region1. Half of the world’s cardiovascular burden is estimated to be in Asia, with a notably higher prevalence of symptomatic heart failure in Southeast Asian countries compared to the global average. In 2018, the prevalence of heart disease in Indonesia was reported to be 1.5%2. Despite the substantial cardiovascular disease (CVD) burden in Indonesia, there is limited knowledge about the characteristics at admission and clinical outcomes of patients with ACS, particularly those presenting with ST-elevation myocardial infarction (STEMI)3. Access to cardiovascular health service in Indonesia is also concerning, with significant disparities in the distribution of catheterization laboratories, which are the standard facilities for intervention that should ideally be accessible within two hours of symptom onset. As of 2022, there were 310 catheterization laboratories in Indonesia, but 208 of these were concentrated on the island of Java4. On the other hand, the implementation of the National Health Insurance (Jaminan Kesehatan Nasional, JKN) in Indonesia has improved healthcare accessibility and encouraged greater health-seeking behavior among its beneficiaries5,6. The primary therapeutic goal in treating STEMI patients is to achieve prompt and complete reperfusion of the affected vessels, which can be accomplished through either fibrinolytic therapy or primary percutaneous coronary intervention (PPCI). Clinical outcomes following reperfusion therapy are influenced by factors such as the type of reperfusion administered, pre-existing risk factors, comorbidities, complications during hospital treatment, and medical adherence7. Despite the high burden of CVD in Indonesia, little is known about the patient registry data and clinical outcomes of patients with ACS, especially those with STEMI. We report a preliminary cohort from the Makassar ACS Registry to evaluate the six-month major adverse cardiovascular and cerebrovascular events (MACCE) among STEMI patients, and identify their predictors. Methods Study population This single-centre, prospective observational study involved STEMI patients who presented to the Makassar Cardiac Centre in Indonesia from July 2018 to June 2020. The primary endpoint was MACCE (including all-cause mortality, heart failure requiring hospitalization, reinfarction, and stroke) during hospitalization, at 30-day and 6-month follow-up. Patients were eligible if they presented to the hospital with symptoms suggestive of myocardial infarction, and had a confirmed diagnosis of STEMI documented in the medical record. Patients who died immediately upon arrival at the emergency department or whose diagnosis remained uncertain were excluded. The diagnosis of STEMI was made by cardiologists and recorded in medical records, following the 2017 European Society of Cardiology (ESC) guidelines for STEMI8. The study included patients who underwent reperfusion therapy, either PPCI or fibrinolysis, as well as those without reperfusion. All patients received standard therapy for acute STEMI, consisting of dual antiplatelet therapy (DAPT) with acetylsalicylic acid and clopidogrel, and a parenteral or subcutaneous anticoagulant (i.e. unfractionated heparin, fondaparinux, or enoxaparin) in accordance with the hospital protocol. DAPT was continued for at least one year following PCI, or adjusted based on individual bleeding and thrombotic risk. Patients in the fibrinolysis group received streptokinase or alteplase, whereas non-reperfused patients were managed with optimal medical therapy, including DAPT and unfractionated heparin, as clinically indicated. Data collection and follow-up We employed a consecutive sampling approach, enrolling all eligible STEMI patients during the study period. We collected baseline data from the Makassar ACS registry and through questionnaire interviews. Sociodemographic information, clinical profiles, and cardiovascular risk factors were recorded. Clinical data were prospectively gathered at the time of hospital admission through physical examinations, electrocardiogram, echocardiography, laboratory tests, and coronary angiography. Laboratory assessments, including cardiac enzymes, were conducted upon hospital arrival. Plasma glucose, HbA1c, and lipid profiles were measured within 24 h of admission, following a minimum 8-h fast for all patients. All blood samples were analyzed using standardized methods in the hospital laboratory. Follow-ups were actively conducted through direct interviews during outpatient clinic visits, telephone interviews, and by reviewing hospital medical records. The primary endpoints were in-hospital, 30-day, and 6-month all-cause mortality rates, as well as composite MACCE, which included cardiac and non-cardiac mortality, heart failure requiring hospitalization, reinfarction, and stroke. In addition, medication adherence was evaluated at the six-month follow-up using the 10-item Medication Adherence Rating Scale (MARS), which has been translated and validated. Statistical analysis Continuous variables were expressed as mean ± SD, while categorical variables were presented as number (percentage). Skewed data were represented as median (Q1–Q3). Baseline characteristics, clinical profiles, and hospitalization management were stratified into groups based on reperfusion methods: primary percutaneous coronary intervention, fibrinolytic therapy, and no reperfusion. Mortality rates and composite MACCE at in-hospital, 30-day, and 6-month intervals post-admission were calculated. Cumulative survival over the six-month follow-up period was estimated using Kaplan–Meier analysis, and survival differences between the reperfusion group (fibrinolytic therapy and PPCI) and the non-reperfusion group were assessed with the log-rank test. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify independent predictors of six-month MACCE, based on the cumulative incidence of events from index admission through six months. Particular attention was given to the effect of reperfusion status. Multivariable models were adjusted for potential confounders, including sex, age, symptom onset, smoking status, hypertension, obesity, dyslipidemia, Killip class, anterior MI, estimated glomerular filtration rate (eGFR), admission hyperglycemia, left ventricular ejection fraction (LVEF), medication adherence, and duration of hospitalization. Results are presented as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). A 95% CI not including one, indicative of a two-sided p-value < 0.05, was considered statistically significant. All statistical analyses were conducted using SPSS version 26.0 for Mac (IBM Corp., Armonk, N.Y., USA). Results We recruited 365 patients with a mean age of 57.1 ± 10.3, and predominantly male (n = 294, 80.5%). Majority of the patients (n = 206, 56.4%) received reperfusion therapy, with 104 (28.5%) underwent PPCI and 102 (27.9%) received fibrinolysis. Smoking was the most common risk factor, found in 71.5% (n = 261) of cases, with 47.4% (n = 173) being active smokers. Other notable risk factors included diabetes mellitus in 25.2% (n = 92) of patients, hypertension in 51.8% (n = 189), and obesity in 35.3% (n = 129). Patients who did not undergo or refused reperfusion were older (59.3 ± 9.8 years) and had lower levels of education compared to those who received reperfusion. Additionally, patients undergoing PPCI were older (56.7 ± 11.5 years) than those receiving fibrinolytic therapy (53.8 ± 8.8 years) (p < 0.001). Obesity was less common in the non-reperfusion group (26.4%, n = 42) compared to the PPCI (38.5%, n = 40) and fibrinolytic therapy groups (46.1%, n = 47) (p = 0.004). A detailed overview of patient characteristics is provided in Table 1.Table 1Baseline characteristics of the STEMI cohort at hospital admission.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Male89 (85.6)83 (81.4)122 (76.7)294 (80.5)0.202Age (years)56.7 ± 11.553.8 ± 8.859.3 ± 9.857.1 ± 10.3 < 0.001*BMI (kg/m2)24.2 ± 2.624.8 ± 3.123.7 ± 2.524.1 ± 2.80.007*Obesitya40 (38.5)47 (46.1)42 (26.4)129 (35.3)0.004*Current smoker56 (53.8)48 (47.1)69 (43.4)173 (47.4)0.251Former smoker82 (78.8)75 (73.5)104 (65.4)261 (71.5)0.053Previous hypertension53 (51.0)49 (48.0)87 (54.7)189 (51.8)0.563Previous DM24 (23.1)23 (22.5)45 (28.3)92 (25.2)0.487PreviousHypercholesterolemia14 (13.5)13 (12.7)16 (10.1)43 (11.8)0.662Previous MIb2 (1.9)6 (5.9)7 (4.4)15 (4.1)0.333Low education level36 (34.6)23 (22.5)65 (40.9)124 (34.0)0.009*Referral from other hospital84 (80.8)83 (81.4)128 (80.5)295 (80.8)0.985Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aObesity was define BMI ≥ 25 kg/m2.bComparison was done using Fisher’s Exact test.STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coroanry Intervention; BMI = Body Mass Index; DM = Diabetes Mellitus;*p < 0.05. Table 1Baseline characteristics of the STEMI cohort at hospital admission.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Male89 (85.6)83 (81.4)122 (76.7)294 (80.5)0.202Age (years)56.7 ± 11.553.8 ± 8.859.3 ± 9.857.1 ± 10.3 < 0.001*BMI (kg/m2)24.2 ± 2.624.8 ± 3.123.7 ± 2.524.1 ± 2.80.007*Obesitya40 (38.5)47 (46.1)42 (26.4)129 (35.3)0.004*Current smoker56 (53.8)48 (47.1)69 (43.4)173 (47.4)0.251Former smoker82 (78.8)75 (73.5)104 (65.4)261 (71.5)0.053Previous hypertension53 (51.0)49 (48.0)87 (54.7)189 (51.8)0.563Previous DM24 (23.1)23 (22.5)45 (28.3)92 (25.2)0.487PreviousHypercholesterolemia14 (13.5)13 (12.7)16 (10.1)43 (11.8)0.662Previous MIb2 (1.9)6 (5.9)7 (4.4)15 (4.1)0.333Low education level36 (34.6)23 (22.5)65 (40.9)124 (34.0)0.009*Referral from other hospital84 (80.8)83 (81.4)128 (80.5)295 (80.8)0.985Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aObesity was define BMI ≥ 25 kg/m2.bComparison was done using Fisher’s Exact test.STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coroanry Intervention; BMI = Body Mass Index; DM = Diabetes Mellitus;*p < 0.05. Baseline characteristics of the STEMI cohort at hospital admission. Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables. aObesity was define BMI ≥ 25 kg/m2. bComparison was done using Fisher’s Exact test. STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coroanry Intervention; BMI = Body Mass Index; DM = Diabetes Mellitus; *p < 0.05. Table 2 summarizes the clinical characteristics and laboratory parameters at hospital admission. Overall, 55.3% (n = 202) of patients presented with anterior MI, 23.0% (n = 84) had reduced renal function, 16.7% (n = 61) had an LVEF ≤ 35%, and 25.2% (n = 92) were classified as Killip class ≥ 2. Compared with the reperfusion groups, patients in the non-reperfusion group more frequently exhibited Killip class ≥ 2, anemia, lower estimated glomerular filtration rate (eGFR), and higher Troponin I levels (all p ≤ 0.001). Significant differences in TIMI scores were observed across reperfusion groups (p < 0.001), as confirmed by post hoc Bonferroni-adjusted analyses. Median TIMI scores were lower in the fibrinolysis group compared with both the PPCI and non-reperfusion groups (both p < 0.001), as shown in Fig. 1.Table 2Clinical presentation of the STEMI cohort at hospital admission.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Systolic BP (mmHg)126.5 ± 24.9130.8 ± 25.3128.5 ± 26.8128.6 ± 25.80.480Diastolic BP (mmHg)78.6 ± 15.182.0 ± 16.780.1 ± 16.480.2 ± 16.10.325Heart rate (x/min)81.4 ± 20.381.3 ± 20.485.1 ± 22.383.0 ± 21.20.260DP (× 103 mmHg/min)10.3 ± 3.310.7 ± 3.610.9 ± 3.610.7 ± 3.50.382Killip class ≥ 222 (21.2)15 (14.7)55 (34.6)92 (25.2)0.001*Anterior MI63 (60.6)46 (45.1)93 (58.5)202 (55.3)0.047*RBG (mg/dL)a134 (111.3–184.5)148 (118.8–221.0)136 (108.0–180.0)138 (112.5–191.0)0.066Hyperglycemiab48 (46.2)54 (52.9)70 (44.0)172 (47.1)0.361Ejection Fraction (%)43.4 ± 8.543.9 ± 8.842.4 ± 8.143.1 ± 8.40.312LVEF ≤ 35%18 (17.3)13 (12.7)30 (18.9)61 (16.7)0.425eGFR (ml/min)86.0 ± 30.193.0 ± 27.872.8 ± 32.182.2 ± 31.6 < 0.001*eGFR < 60 ml/min21 (20.2)12 (11.8)51 (32.1)84 (23.0)0.001*LaboratoriumTot. cholesterol (mmol/L)185.8 ± 38.7195.7 ± 52.1186.9 ± 49.8189.0 ± 47.70.247Triglyceride (mmol/L)a117.0 (93.0–150.0)130.5 (97.8–168.3)16.0 (90.0–144.0)119.0 (93.0–151.5)0.050LDL cholesterol (mmol/L)111.1 ± 27.5112.1 ± 28.3111.5 ± 29.8111.6 ± 28.70.972HDL cholesterol (mmol/L)39.3 ± 7.939.7 ± 8.138.7 ± 10.839.1 ± 9.30.656Creatinin (µmol/L)0.9 ± 0.30.9 ± 0.31.2 ± 0.91.0 ± 0.6 < 0.001*Haemoglobin (g/dL)14.1 ± 1.714.5 ± 1.913.5 ± 2.214.0 ± 2.0 < 0.001*Haematocrit (%)40.1 ± 4.841.4 ± 5.338.6 ± 5.939.8 ± 5.5 < 0.001*Leucocyte (per mm3)13,287. 5 ± 3837.814,354.4 ± 4876.613,003.5 ± 4200.413,461.9 ± 4330.00.043*Potassium (mEq/L)4.3 ± 0.54.1 ± 0.54.2 ± 0.64.2 ± 0.50.190Troponin I (× 103 ng/L)4.3 (1.0–10.0)1.8 (0.5–9.8)10.0 (6.3–10.0)9.1 (1.2–10.0) < 0.001*TIMI scorea4 (3–6)3 (2–4)4 (3–6)4 (3–6) < 0.001*TIMI score > 535 (33.7)13 (12.7)51 (32.1)99 (27.1)0.001Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test.bHyperglycemia was define random blood glucose > 140 mg/dL at admission.PCI = Percutaneous Coronary Intervention; DP = double product; BP = Blood pressure; STEMI = ST-Elevation Myocardial Infarction; RBG = Random blood glucose; LVEF = Left Ventricular Ejection Fraction; eGFR = Glomerular Filtration Rate.*p < 0.05.Fig. 1Comparison of TIMI scores across reperfusion groups in STEMI patients. Significance values were adjusted by the Bonferroni correction for multiple tests. *p < 0.05. Table 2Clinical presentation of the STEMI cohort at hospital admission.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Systolic BP (mmHg)126.5 ± 24.9130.8 ± 25.3128.5 ± 26.8128.6 ± 25.80.480Diastolic BP (mmHg)78.6 ± 15.182.0 ± 16.780.1 ± 16.480.2 ± 16.10.325Heart rate (x/min)81.4 ± 20.381.3 ± 20.485.1 ± 22.383.0 ± 21.20.260DP (× 103 mmHg/min)10.3 ± 3.310.7 ± 3.610.9 ± 3.610.7 ± 3.50.382Killip class ≥ 222 (21.2)15 (14.7)55 (34.6)92 (25.2)0.001*Anterior MI63 (60.6)46 (45.1)93 (58.5)202 (55.3)0.047*RBG (mg/dL)a134 (111.3–184.5)148 (118.8–221.0)136 (108.0–180.0)138 (112.5–191.0)0.066Hyperglycemiab48 (46.2)54 (52.9)70 (44.0)172 (47.1)0.361Ejection Fraction (%)43.4 ± 8.543.9 ± 8.842.4 ± 8.143.1 ± 8.40.312LVEF ≤ 35%18 (17.3)13 (12.7)30 (18.9)61 (16.7)0.425eGFR (ml/min)86.0 ± 30.193.0 ± 27.872.8 ± 32.182.2 ± 31.6 < 0.001*eGFR < 60 ml/min21 (20.2)12 (11.8)51 (32.1)84 (23.0)0.001*LaboratoriumTot. cholesterol (mmol/L)185.8 ± 38.7195.7 ± 52.1186.9 ± 49.8189.0 ± 47.70.247Triglyceride (mmol/L)a117.0 (93.0–150.0)130.5 (97.8–168.3)16.0 (90.0–144.0)119.0 (93.0–151.5)0.050LDL cholesterol (mmol/L)111.1 ± 27.5112.1 ± 28.3111.5 ± 29.8111.6 ± 28.70.972HDL cholesterol (mmol/L)39.3 ± 7.939.7 ± 8.138.7 ± 10.839.1 ± 9.30.656Creatinin (µmol/L)0.9 ± 0.30.9 ± 0.31.2 ± 0.91.0 ± 0.6 < 0.001*Haemoglobin (g/dL)14.1 ± 1.714.5 ± 1.913.5 ± 2.214.0 ± 2.0 < 0.001*Haematocrit (%)40.1 ± 4.841.4 ± 5.338.6 ± 5.939.8 ± 5.5 < 0.001*Leucocyte (per mm3)13,287. 5 ± 3837.814,354.4 ± 4876.613,003.5 ± 4200.413,461.9 ± 4330.00.043*Potassium (mEq/L)4.3 ± 0.54.1 ± 0.54.2 ± 0.64.2 ± 0.50.190Troponin I (× 103 ng/L)4.3 (1.0–10.0)1.8 (0.5–9.8)10.0 (6.3–10.0)9.1 (1.2–10.0) < 0.001*TIMI scorea4 (3–6)3 (2–4)4 (3–6)4 (3–6) < 0.001*TIMI score > 535 (33.7)13 (12.7)51 (32.1)99 (27.1)0.001Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test.bHyperglycemia was define random blood glucose > 140 mg/dL at admission.PCI = Percutaneous Coronary Intervention; DP = double product; BP = Blood pressure; STEMI = ST-Elevation Myocardial Infarction; RBG = Random blood glucose; LVEF = Left Ventricular Ejection Fraction; eGFR = Glomerular Filtration Rate.*p < 0.05. Clinical presentation of the STEMI cohort at hospital admission. Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables. aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test. bHyperglycemia was define random blood glucose > 140 mg/dL at admission. PCI = Percutaneous Coronary Intervention; DP = double product; BP = Blood pressure; STEMI = ST-Elevation Myocardial Infarction; RBG = Random blood glucose; LVEF = Left Ventricular Ejection Fraction; eGFR = Glomerular Filtration Rate. *p < 0.05. Comparison of TIMI scores across reperfusion groups in STEMI patients. Significance values were adjusted by the Bonferroni correction for multiple tests. *p < 0.05. Table 3 outlines the management during hospitalization. The median ischemic time for patients receiving reperfusion therapy was 405 min (IQR 295–570). Of the 102 patients who received fibrinolytic therapy, 19.6% (n = 20) experienced treatment failure, and 9 (8.8%) subsequently underwent rescue PCI. Of the 104 patients undergoing PPCI, 43.3% (n = 45) were diagnosed with three-vessel disease. STEMI patients who did not receive reperfusion had longer delays from symptom onset to first medical contact (FMC) and from onset to hospital admission (p < 0.001). Additionally, a higher rate of complications, including ventricular septal rupture, acute mitral regurgitation, cardiogenic shock, heart failure, acute bleeding, ischemic stroke, hemorrhagic stroke, renal failure, cardiac arrest, and respiratory failure, was observed in patients who did not undergo reperfusion compared to those treated with PPCI or fibrinolysis (40.9% (n = 65) vs. 28.8% (n = 30) vs. 24.5% (n = 25), p = 0.013).Table 3Management of the STEMI cohort from hospital admission to 6-month follow-up.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p-valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Onset angina-FMC (min)a128.5 (60–540)60 (57.5–128.8)360 (120–900)180 (60–570) < 0.001*Onset angina-ER (min)a827 (364.3–2181.8)331 (242.8–476.3)1243 (803–2786)750 (349.5–1683) < 0.001*Ischaemic time (min)b440 (295–625)397.5 (295–502.5)N/A405 (295–570)c0.120dDoor to device time (min)132 (85–650)eN/AN/AN/AN/ADoor to needle time (min)N/A57.1 ± 29.2f.N/AN/AN/ACoronary angiography 3VD45 (43.3)N/AN/AN/AN/AFibrinolytic agent, alteplaseN/A91 (89.2)N/AN/AN/AFibrinolytic successfulN/A82 (80.4)N/AN/AN/APost-fibrinolytic managementCA and PCI (if indicated)N/A19 (18.6)N/AN/AN/ARescue PCIN/A9 (8.8)N/AN/AN/ALength of stay (days)7.7 ± 4.27.4 ± 3.87.2 ± 3.57.4 ± 3.80.607Complications at hospitalg30 (28.8)25 (24.5)65 (40.9)120 (32.9)0.013*Medication adherenceh45 (46.9)47 (48.5)52 (37.7)144 (43.5)0.191Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test.bMeasure (in minute) since symptom of ischemia until got reperfusion therapy. Ischaemic time = onset PJT + delay (door to device time in primary PCI and door to needle time in fibrinolytic).cData is available in all patients with fibrinolytic and 47 patients (45.2%) in primary PCI group.dComparison was done using Mann–Whitney test.eData is available in 63 (60.6%) patients on primary PCI group.fData is available in 102 (100%) patients on fibrinolytic group.gConsists of ventricular septal rupture (VSR), acute mitral regurgitation (MR), shock, heart failure, acute bleeding, ischaemic stroke, haemorraghe stroke, renal failure, cardiac arrest, dan respiratory failure.hData is available in 331 (90.7%) patients: 96 (92.3%) on primary PCI group, 97 (95.1%) on fibrinolytic group, and 138 (86.8%) on without reperfusion group.STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; FMC = First Medical Contact; PJT = Pusat Jantung Terpadu RS Wahidin Sudirohusodo Makassar; CA = Coronary Angiography; N/A = Not Applicable.*p < 0.05. Table 3Management of the STEMI cohort from hospital admission to 6-month follow-up.VariablesWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p-valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)Onset angina-FMC (min)a128.5 (60–540)60 (57.5–128.8)360 (120–900)180 (60–570) < 0.001*Onset angina-ER (min)a827 (364.3–2181.8)331 (242.8–476.3)1243 (803–2786)750 (349.5–1683) < 0.001*Ischaemic time (min)b440 (295–625)397.5 (295–502.5)N/A405 (295–570)c0.120dDoor to device time (min)132 (85–650)eN/AN/AN/AN/ADoor to needle time (min)N/A57.1 ± 29.2f.N/AN/AN/ACoronary angiography 3VD45 (43.3)N/AN/AN/AN/AFibrinolytic agent, alteplaseN/A91 (89.2)N/AN/AN/AFibrinolytic successfulN/A82 (80.4)N/AN/AN/APost-fibrinolytic managementCA and PCI (if indicated)N/A19 (18.6)N/AN/AN/ARescue PCIN/A9 (8.8)N/AN/AN/ALength of stay (days)7.7 ± 4.27.4 ± 3.87.2 ± 3.57.4 ± 3.80.607Complications at hospitalg30 (28.8)25 (24.5)65 (40.9)120 (32.9)0.013*Medication adherenceh45 (46.9)47 (48.5)52 (37.7)144 (43.5)0.191Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables.aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test.bMeasure (in minute) since symptom of ischemia until got reperfusion therapy. Ischaemic time = onset PJT + delay (door to device time in primary PCI and door to needle time in fibrinolytic).cData is available in all patients with fibrinolytic and 47 patients (45.2%) in primary PCI group.dComparison was done using Mann–Whitney test.eData is available in 63 (60.6%) patients on primary PCI group.fData is available in 102 (100%) patients on fibrinolytic group.gConsists of ventricular septal rupture (VSR), acute mitral regurgitation (MR), shock, heart failure, acute bleeding, ischaemic stroke, haemorraghe stroke, renal failure, cardiac arrest, dan respiratory failure.hData is available in 331 (90.7%) patients: 96 (92.3%) on primary PCI group, 97 (95.1%) on fibrinolytic group, and 138 (86.8%) on without reperfusion group.STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; FMC = First Medical Contact; PJT = Pusat Jantung Terpadu RS Wahidin Sudirohusodo Makassar; CA = Coronary Angiography; N/A = Not Applicable.*p < 0.05. Management of the STEMI cohort from hospital admission to 6-month follow-up. Values are n (%) or mean ± SD, unless otherwise stated. Comparison of baseline characteristics was performed using One-way ANOVA test for continuous variables and Pearson Chi-square test for categorical variables. aValues are medians (Q1–Q3). Comparison was done using Kruskal–Wallis test. bMeasure (in minute) since symptom of ischemia until got reperfusion therapy. Ischaemic time = onset PJT + delay (door to device time in primary PCI and door to needle time in fibrinolytic). cData is available in all patients with fibrinolytic and 47 patients (45.2%) in primary PCI group. dComparison was done using Mann–Whitney test. eData is available in 63 (60.6%) patients on primary PCI group. fData is available in 102 (100%) patients on fibrinolytic group. gConsists of ventricular septal rupture (VSR), acute mitral regurgitation (MR), shock, heart failure, acute bleeding, ischaemic stroke, haemorraghe stroke, renal failure, cardiac arrest, dan respiratory failure. hData is available in 331 (90.7%) patients: 96 (92.3%) on primary PCI group, 97 (95.1%) on fibrinolytic group, and 138 (86.8%) on without reperfusion group. STEMI = ST-Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; FMC = First Medical Contact; PJT = Pusat Jantung Terpadu RS Wahidin Sudirohusodo Makassar; CA = Coronary Angiography; N/A = Not Applicable. *p < 0.05. Figure 2 illustrates the clinical outcomes at 30-day and 6-month follow-ups. The incidence of MACCE was 19.5% (n = 71) during the index hospitalization, with an additional 3.6% (n = 13) new events observed at 30 days and 33.2% (n = 121) new events at 6 months. Six-month mortality was significantly higher among patients without reperfusion compared to those who underwent PPCI or fibrinolysis (26.4% vs. 17.3% vs. 13.7%, p = 0.030). A detailed distribution of MACCE events at 30 days and 6 months across reperfusion groups is presented in Table 4. In survival analysis using the Mantel–Cox log-rank test, STEMI patients without reperfusion therapy demonstrated significantly lower survival rates compared with those who received reperfusion (p = 0.023), as shown in Fig. 3.Fig. 2Clinical outcomes showing new adverse events at 30-day and 6-month follow-up after discharge in the STEMI cohort. Values are n (%). Comparison was performed using Pearson Chi-square test or Fischer’s Exact test. MACCE at 30 days and 6 months were calculated from the date of hospital discharge. MACCE, Major Adverse Cardio-cerebro Vascular Events; PCI, Percutaneous Coronary Intervention. *p < 0.05.Table 4Cumulative incidence of major adverse cardio-cerebrovascular events (MACCE) at 30 days and 6 months in STEMI Patients with and without reperfusion therapy.MACCEaWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p-valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)In hospital Heart failure11 (10.6)5 (4.9)15 (9.4)31 (8.5)0.293 Stroke1 (1.0)5 (4.9)2 (1.3)8 (2.2)0.102 Re-infarction––––N/A Mortality8 (7.7)5 (4.9)21 (13.2)34 (9.3)0.06330 days Heart failure12 (11.5)8 (7.8)16 (10.1)36 (9.9)0.669 Stroke1 (1.0)5 (4.9)2 (1.3)8 (2.2)0.102 Re-infarction1 (1.0)0 (0.0)2 (1.3)3 (0.8)0.790 Mortality8 (7.7)5 (4.9)26 (16.4)39 (10.7)0.007*6 months Heart failure20 (19.2)19 (18.6)42 (26.4)81 (22.2)0.059 Stroke3 (2.9)5 (4.9)5 (3.1)13 (3.6)0.720 Re-infarction12 (11.5)11 (10.8)5 (3.1)28 (7.7)0.017* Mortality18 (17.3)14 (13.7)42 (26.4)74 (20.3)0.030*Values are n (%). Comparison was performed using Pearson Chi-Square or Fisher’s Exact test.aA patient can experience more than 1 MACCE at the same time.STEMI = ST-Elevation Myocardial Infarction; MACCE = Major Adverse Cardio-cerebro Vascular Events; PCI = Percutaneous Coronary Intervention.*p < 0.05.Fig. 3Kaplan–Meier curves for cumulative 6-month survival, comparing the reperfusion vs. non-reperfusion groups. Comparison was performed using LR (Mantel–Cox) test. LR, log rank; PCI, percutaneous coronary intervention. *p < 0.05. Clinical outcomes showing new adverse events at 30-day and 6-month follow-up after discharge in the STEMI cohort. Values are n (%). Comparison was performed using Pearson Chi-square test or Fischer’s Exact test. MACCE at 30 days and 6 months were calculated from the date of hospital discharge. MACCE, Major Adverse Cardio-cerebro Vascular Events; PCI, Percutaneous Coronary Intervention. *p < 0.05. Table 4Cumulative incidence of major adverse cardio-cerebrovascular events (MACCE) at 30 days and 6 months in STEMI Patients with and without reperfusion therapy.MACCEaWith reperfusionWithout reperfusion (n = 159)Total (n = 365)p-valuesPrimary PCI (n = 104)Fibrinolytic (n = 102)In hospital Heart failure11 (10.6)5 (4.9)15 (9.4)31 (8.5)0.293 Stroke1 (1.0)5 (4.9)2 (1.3)8 (2.2)0.102 Re-infarction––––N/A Mortality8 (7.7)5 (4.9)21 (13.2)34 (9.3)0.06330 days Heart failure12 (11.5)8 (7.8)16 (10.1)36 (9.9)0.669 Stroke1 (1.0)5 (4.9)2 (1.3)8 (2.2)0.102 Re-infarction1 (1.0)0 (0.0)2 (1.3)3 (0.8)0.790 Mortality8 (7.7)5 (4.9)26 (16.4)39 (10.7)0.007*6 months Heart failure20 (19.2)19 (18.6)42 (26.4)81 (22.2)0.059 Stroke3 (2.9)5 (4.9)5 (3.1)13 (3.6)0.720 Re-infarction12 (11.5)11 (10.8)5 (3.1)28 (7.7)0.017* Mortality18 (17.3)14 (13.7)42 (26.4)74 (20.3)0.030*Values are n (%). Comparison was performed using Pearson Chi-Square or Fisher’s Exact test.aA patient can experience more than 1 MACCE at the same time.STEMI = ST-Elevation Myocardial Infarction; MACCE = Major Adverse Cardio-cerebro Vascular Events; PCI = Percutaneous Coronary Intervention.*p < 0.05. Cumulative incidence of major adverse cardio-cerebrovascular events (MACCE) at 30 days and 6 months in STEMI Patients with and without reperfusion therapy. Values are n (%). Comparison was performed using Pearson Chi-Square or Fisher’s Exact test. aA patient can experience more than 1 MACCE at the same time. STEMI = ST-Elevation Myocardial Infarction; MACCE = Major Adverse Cardio-cerebro Vascular Events; PCI = Percutaneous Coronary Intervention. *p < 0.05. Kaplan–Meier curves for cumulative 6-month survival, comparing the reperfusion vs. non-reperfusion groups. Comparison was performed using LR (Mantel–Cox) test. LR, log rank; PCI, percutaneous coronary intervention. *p < 0.05. Figure 4 illustrates the forest plot of factors associated with 6-month MACCE in our cohort. Several significant independent factors were identified, including age ≥ 60 years (HR 1.45 [95% CI 1.03–2.03], p = 0.032), Killip class ≥ 2 (HR 2.06 [95% CI 1.42–2.99], p < 0.001), anterior myocardial infarction (HR 1.47 [95% CI 1.05–2.06], p = 0.024), eGFR < 60 mL/min (HR 1.57 [95% CI 1.09–2.25], p = 0.015), non-adherence to medications (HR 1.70 [95% CI 1.23–2.35], p = 0.001), and length of stay (LOS) of ≥ 8 days (HR 1.48 [95% CI 1.07–2.05], p = 0.018). The absence of reperfusion in our cohort was not statistically significant in the multivariable analysis. The results remained non-significant for both in-hospital and 6-month all-cause mortality.Fig. 4Forest plot on multivariable Hazard Ratios (HR) for 6-month MACCE. Analysis was performed using multivariable Cox proporsional hazard analysis. Elderly was defined as > 60 years, according to the Indonesian Ministry of Health. *p < 0.05. Forest plot on multivariable Hazard Ratios (HR) for 6-month MACCE. Analysis was performed using multivariable Cox proporsional hazard analysis. Elderly was defined as > 60 years, according to the Indonesian Ministry of Health. *p < 0.05. Discussion In this study, we observed a high incidence of six-month MACCE among STEMI patients in eastern Indonesia, particularly in those who did not undergo reperfusion therapy. The mean age of STEMI patients in our cohort was intermediate compared with neighboring Asian countries, older than reported in Malaysia but younger than in Thailand9,10. Patients receiving reperfusion therapy were notably younger than those who did not. This pattern aligns with previous reports and likely reflects factors such as cognitive impairment, delayed presentation, physician concern over bleeding risk, patient preference, and age-related treatment bias11. Most STEMI patients in Eastern Indonesia were male, consistent with regional trends. However, traditional cardiovascular risk factors were less prevalent than in neighboring countries. Hypertension affected fewer patients than in Malaysia (52.9%), Thailand (62.8%), and Singapore (56.6%), while diabetes prevalence was also lower than in Malaysia (37.6%), Singapore (32.3%), and Thailand (37.0%)9,10,12. Smoking was the most prevalent risk factor among STEMI patients in our cohort and may partly explain the relatively younger age at presentation. This pattern aligns with regional trends, with higher smoking rates in Malaysia than Thailand9,10. Boulos et al. reported that STEMI occurs significantly earlier in smokers than non-smokers13. In Eastern Indonesia, early initiation (ages 14–25), historically high prevalence, and recent cessation patterns likely contribute14. These findings have important implications for secondary prevention, as cardiovascular risk remains elevated in former smokers even after > 5 years of cessation15. STEMI patients in our cohort faced longer delays to hospitalization than in neighboring countries, with 300 min in Malaysia and 145 min in Singapore. Factors include gender, symptom severity, patient and bystander actions, and transportation16,17. Despite PCI being the most effective therapy, East Indonesia has only 21 catheterization laboratories, 18 in Sulawesi, two in Maluku, and one in Papua4, limiting timely access across this vast region. These patients also exhibited poorer outcomes on hospital admission9. Reduced renal function and elevated troponin I levels in those without reperfusion likely reflect prolonged symptom-to-hospitalization times, with 82.4% classified as late presenters. Extended delays increase ischemic time, enlarge the myocardial necrosis area, and raise the risk of complications, including acute kidney injury18,19. Median TIMI scores were significantly lower in the fibrinolysis group than in the PPCI and non-reperfusion groups, reflecting real-world selection bias. Fibrinolysis was primarily given to hemodynamically stable patients without high-risk features, often at peripheral hospitals or during off-hours. Patients with higher TIMI scores, indicating greater ischemic burden or instability, were more likely triaged to PPCI or received no reperfusion if contraindicated or delayed. In this study, nearly half of STEMI patients did not receive reperfusion, primarily due to delayed presentation, with most arriving beyond the 12-h therapeutic window. Our center follows the Indonesian Heart Association (PERKI) algorithm, prioritizing primary PCI, with fibrinolysis as an alternative. Patients presenting after 24 h are generally managed medically unless high-risk features indicate intervention20. Additional barriers to reperfusion in our cohort included patient refusal, contraindications to fibrinolysis, spontaneous reperfusion, and non-clinical factors such as insurance limitations. Common contraindications were active bleeding, recent gastrointestinal hemorrhage, and ischemic stroke within six months. Most fibrinolysis patients received alteplase, with generally favorable outcomes. These findings underscore the impact of late presentation and the need to address patient-level, clinical, and systemic factors in resource-limited settings. In this study, clinical outcomes did not differ significantly between patients who underwent reperfusion via PPCI or fibrinolysis. This finding contrasts with prior studies demonstrating lower mortality among STEMI patients treated with PPCI compared to fibrinolysis21. Differences in patient characteristics, healthcare infrastructure, and treatment delays may account for these discrepancies. Our results underscore that prolonged ischemic time can diminish the advantages of PPCI; in such settings, timely fibrinolysis may offer a more effective initial strategy21. Previous research supports this view, showing that early fibrinolysis can achieve mortality outcomes comparable to PPCI, particularly in resource-limited regions where PCI is not readily available within 24 hours22. This challenge remains relevant in Eastern Indonesia. Furthermore, other studies have reported no significant long-term mortality differences up to five years between PPCI, fibrinolysis, and pharmaco-invasive approaches23. Late presentation was the primary reason for non-reperfusion, reflecting delays in symptom recognition and hospital arrival. Consistent with Brown et al., diagnostic delays and atypical symptom presentation are associated with higher short-term mortality24. These findings highlight the critical need to improve public awareness of myocardial infarction symptoms and promote early emergency care, as timely hospital arrival is essential to maximize the benefits of reperfusion therapy. An unexpected finding was the lower 6-month reinfarction rate in the non-reperfusion group compared with those receiving PPCI or fibrinolysis. This paradox likely reflects survivor bias and baseline risk differences. Patients without reperfusion experienced higher early mortality during hospitalization and within 30 day, reducing the number at risk for reinfarction during follow-up. Conversely, survivors of reperfusion therapy remained susceptible to later ischemic events, such as stent thrombosis or recurrent occlusion. Reperfusion itself may also contribute to reinfarction through incomplete revascularization, accelerated atherosclerosis, or reperfusion injury. Thus, the lower reinfarction rate among non-reperfused patients likely reflects competing risks rather than a protective effect. In our study, reperfusion times for both PPCI and fibrinolytic therapy frequently exceeded guideline-recommended targets. Most PPCI patients presented beyond 12 h after symptom onset, reflecting significant pre-hospital delays. Prior evidence demonstrates that STEMI patients undergoing PPCI within five hours of symptom onset achieve markedly better myocardial reperfusion and clinical outcomes than those with longer delays25. Prolonged ischemic times in our cohort were likely attributable to low public awareness of cardiac symptoms, limited transportation access, financial barriers, and delayed or inaccurate diagnoses at referring hospitals or primary healthcare facilities17. In many rural and remote areas of Eastern Indonesia, primary hospitals lack fibrinolytic capability, leading to prolonged ischemic times and loss of eligibility for reperfusion by the time patients reach tertiary centers. Moreover, the referral hospital itself was not fully optimized for PPCI delivery, with limited infrastructure and trained personnel during off-hours. This aligns with our previous report17 and with prior studies showing that off-hour presentation is associated with longer door-to-balloon times and higher mortality rates26. In the present study, factors significantly associated with an increased risk of MACCE included older age, Killip class ≥ 2, anterior infarction, impaired renal function, medication non-adherence, and prolonged hospitalization. These results are consistent with previous reports demonstrating the prognostic value of the Killip classification for both short- and long-term mortality27. We further showed that Killip class at hospital admission was strongly associated with adverse outcomes within the first six months. Patients with Killip class 2–4 were more likely to be older, female, and have diabetes mellitus, prior heart failure, renal impairment, anemia, anterior infarction, lower admission blood pressure, and multivessel disease28. A substantial proportion of patients in our study did not adhere to post-discharge medications. Good adherence has consistently been associated with improved outcomes, including reduced recurrent events and one-year cardiovascular mortality after myocardial infarction29. In our cohort, six-month composite mortality was notably higher among patients who did not receive reperfusion therapy. Although our registry did not systematically capture outcomes by adherence status, it is plausible that the combination of absent reperfusion and poor adherence to secondary prevention further worsened outcomes. Similar findings have been reported in Indonesia, where non-adherence to guideline-directed therapy increased in-hospital and mid-term mortality among non-reperfused STEMI patients30. However, data on the long-term impact of medication adherence in this population remain limited. Future studies should explore whether adherence has a greater effect on outcomes in non-reperfused patients compared with those receiving reperfusion therapy. In this study, reduced renal function (eGFR < 60 ml/min) was an independent predictor of MACCE and mortality within six months in STEMI patients. Previous studies report that approximately 26% of myocardial infarction patients develop acute kidney injury, which is independently associated with higher short- and long-term morbidity and mortality31,32. Reduced renal function contributes to higher MACCE risk through multiple interrelated mechanisms. It may indicate systemic vascular injury and endothelial dysfunction, which promote atherosclerosis progression and impair myocardial perfusion rather than exerting a direct causal effect. Moreover, chronic kidney impairment is frequently associated with anemia and left ventricular hypertrophy, both of which increase myocardial gen demand and exacerbate ischemia during acute coronary syndromes. Impaired renal clearance can also lead to heightened inflammation, oxidative stress, and neurohormonal activation, further aggravating myocardial injury and adverse remodeling. Collectively, these factors explain the strong association between renal dysfunction and poor cardiovascular outcomes in STEMI patients33. We found that age over 60 years independently predicted six-month MACCE and mortality. Age is a key factor in risk stratification for myocardial infarction, with age ≥ 65 years included in the TIMI risk score for predicting 30-day mortality in STEMI patients34. Previous studies have similarly identified age over 65 years as an important determinant of short-term clinical outcomes in STEMI patients35. We also observed that a hospital length of stay (LOS) exceeding eight days was associated with poorer outcomes. This finding is consistent with Swaminathan et al., who reported that a LOS > 5 days correlated with higher mortality and MACCE rate36. Additionally, a study in Malaysia found that fibrinolytic therapy was linked to longer LOS, increased risk of cardiogenic shock, re-infarction, and death compared with PPCI37. The prolonged LOS and higher MACCE rates in the fibrinolytic group likely reflect greater morbidity and increased healthcare costs relative to patients undergoing PPCI27. WI. Anterior infarction was the most common STEMI presentation, with a higher proportion undergoing PPCI, reflecting its greater prevalence and more severe clinical profile. Previous study has shown larger infarct sizes and an increased risk of MACCE in anterior cases (HR 2.01, 95% CI 1.05–3.83)38. In our cohort, infarct location independently predicted six-month MACCE and mortality. Anterior myocardial infarction is associated with greater reductions in left ventricular ejection fraction, poorer prognosis39, and more pronounced post-infarct remodeling due to irreversible ischemic damage40. This study offers valuable insights into patient characteristics, clinical profiles, therapeutic management, and short- to medium-term outcomes in a resource-limited setting. Its strength lies in focusing on a STEMI population with distinctive demographic and socioeconomic features, which differ from those in high-income countries. These findings highlight unique clinical patterns and challenges, emphasizing the importance of context-specific strategies to guide public health interventions and optimize patient care. Several limitations should be acknowledged. First, this was a single-center study, which may limit generalizability due to variations in resources, management practices, and regional contexts. The high proportion of patients presenting beyond the recommended reperfusion window introduces potential confounding, complicating direct comparisons between reperfusion and non-reperfusion groups. Future studies with detailed timing and clinical data are needed to clarify the effects of reperfusion versus delayed presentation. Second, the absence of coronary angiography data for most patients precluded assessment of lesion severity and its impact on outcomes. Outcome analyses were not stratified by medication adherence, despite substantial non-compliance, which may limit interpretation of mortality differences. Additionally, data on referral distances and inter-hospital transfers were unavailable, both of which could influence treatment delays and the effectiveness of reperfusion strategies. Multi-center studies with systematic angiographic evaluation, adherence monitoring, and referral pathway data are warranted. These findings have important implications for healthcare policy in Eastern Indonesia. Given the long delays from symptom onset to hospital admission and high rates of late presentation, community-based education campaigns should be prioritized to improve symptom recognition and early healthcare seeking. At the systems level, strengthening pre-hospital emergency services and implementing streamlined protocols are essential to reduce ischemic time. Expanding catheterization laboratory capacity and ensuring 24/7 reperfusion availability in regional hospitals, together with robust post-discharge programs to support medication adherence, could substantially reduce mortality and MACCE in this population. Conclusions The high incidence of MACCE at 30 days and 6 months after STEMI in our region are concerning. These outcomes were affected by independent factors, including delays in treatment and restricted access to reperfusion therapies. Patients often faced significant delays from symptom onset to hospital admission, resulting in suboptimal adherence to reperfusion therapy guidelines. To mitigate the elevated rates of adverse outcomes in this population, it is crucial to enhance symptom awareness, accelerate PPCI activation, and reinforce hospital infrastructure and resources for optimal STEMI management.